PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations [1]
A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
Links
[1] https://www.ctsnet.org/jans/pcsk9-inhibition-reduce-cardiovascular-risk-tempering-expectations
[2] https://www.ctsnet.org/home/aprotopapas
[3] http://circres.ahajournals.org/content/120/10/1537
[4] https://www.ctsnet.org/tags/basic-science
[5] https://www.ctsnet.org/taxonomy/clinical-epidemiology
[6] https://www.ctsnet.org/taxonomy/molecular-biology
[7] https://www.ctsnet.org/taxonomy/pharmacology
[8] https://www.ctsnet.org/taxonomy/physiology
[9] https://www.ctsnet.org/tags/cardiac-other
[10] https://www.ctsnet.org/tags/cardiac-pharmacology
[11] https://www.ctsnet.org/tags/cardiac-physiology
[12] https://www.ctsnet.org/taxonomy/cardiac-guidelines
[13] https://www.ctsnet.org/taxonomy/coronary-disease-other
[14] https://www.ctsnet.org/categories/cardiac
[15] https://www.ctsnet.org/taxonomy2018/basic-science
[16] https://www.ctsnet.org/taxonomy2018/cardiac
[17] https://www.ctsnet.org/taxonomy2018/professional-affairs
[18] https://www.ctsnet.org/taxonomy2018/coronary-disease